Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Exploring Mechanisms of Hepatitis C Virus-Associated Xerostomia

Award Number: K22DE032046
ORGANIZATION: NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: TRAINING/TRAINEESHIP
PERIOD OF PERFORMANCE START DATE: 06/20/2024
PERIOD OF PERFORMANCE END DATE: 05/31/2027

Group Awards By:

View Award Description

Exploring Mechanisms of Hepatitis C Virus-Associated Xerostomia - PROJECT SUMMARY/ABSTRACT Chronic hepatitis C virus (HCV) infection remains one of the major causes of chronic liver disease, cirrhosis and liver cancer, and is a major public health issue worldwide, with an estimated prevalence of 170 million people globally. With no prophylactic HCV vaccine available, HCV remains difficult to eradicate. Newer generations of Direct-Acting Antivirals (DAA) are effective in eliminating the virus in up to 95% of the patients, however, this treatment remains out of reach for many individuals. Multiple HCV extrahepatic manifestations (EHM) have been reported in patients with chronic HCV infection including chronic lymphocytic sialadenitis, and sicca syndrome indistinguishable from Sjögren’s syndrome (SS). Yet, the mechanisms of the xerostomia and salivary gland (SG) hypofunction remain controversial. Thus, understanding the clinical aspects of HCV-associated xerostomia is of interest to better assess and manage this symptom. The objectives of this project are to determine the pathophysiologic changes in the minor salivary glands (MSG) and changes in saliva composition associated with chronic HCV infection and correlate these changes with clinical features of SG hypofunction (mentored phase) and to mechanistically describe the HCV-associated xerostomia (independent phase). To achieve this goal, Dr. José Maldonado-Ortiz will work with a mentoring team including Dr. John Chiorini (primary mentor), Dr. Blake Warner (co-mentor), Dr. Raj Gopalakrishnan (collaborator), Dr. Valeria De Giorgi (collaborator), and Nobel laureate Dr. Harvey Alter (collaborator). In Aim 1, the pathophysiologic changes in the MSG of patients with chronic HCV infection will be determined and correlated to xerostomia and clinical features of salivary dysfunction in patients with and without complaints of xerostomia. In Aim 2, the effects of HCV DAA therapy in salivary physiology will be determined and correlated to clinical features of xerostomia. To understand the pathophysiology of chronic HCV-associated SG dysfunction (Aim 1), and the effects of DAA therapy in SG function, MSG biopsies will be collected and used to provide histopathological evidence of SG damage/changes and research tissues to perform RNAseq and scRNAseq, in addition to sialometry, sialochemistry, and ultrasonography of the major SG. Dry mouth and oral health related quality of life instruments will be completed. In Aim 3, the mechanisms of HCV induced salivary gland dysfunction will be determined in vivo. To this end, an adeno-associated virus (AAV) vector expressing the antigenic HCV envelope proteins E1 and E2 will be transferred into the submandibular SG of mice to 1) better understand the HCV/host immune cell interactions and 2) tissue changes that may result in SG dysfunction. In combination, these studies will reveal new information about viral infections and the triggering or initiation of SG diseases such as SS. HCV infection offers a unique opportunity to study viral induced SG dysfunction and can provide mechanistic data on the role of viruses in driving inflammation, dysfunction, and damage in the SG.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $242,972 )
2025	2025	HEALTHPARTNERS INSTITUTE	8170 33RD AVE S	MINNEAPOLIS	MN	55425	HENNEPIN	USA	Oral Diseases and Disorders Research	000	3	6/3/2025	NON-COMPETING CONTINUATION	$242,972
														Subtotal = $242,972

Issue Date FY: 2024 ( Subtotal = $248,264 )
2024	2024	HEALTHPARTNERS INSTITUTE	8170 33RD AVE S	MINNEAPOLIS	MN	55425	HENNEPIN	USA	Oral Diseases and Disorders Research	000	2	6/20/2024	EXTENSION WITH OR WITHOUT FUNDS	$248,264
														Subtotal = $248,264

Grand Total All Awards = $491,236

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Exploring Mechanisms of Hepatitis C Virus-Associated Xerostomia

Award Number: K22DE032046

ORGANIZATION: NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: TRAINING/TRAINEESHIP

PERIOD OF PERFORMANCE START DATE: 06/20/2024

PERIOD OF PERFORMANCE END DATE: 05/31/2027

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer